Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: The Calgary BMT Program experience

Bone Marrow Transplantation

Volumn 36, Issue 7, 2005, Pages 591-596

  Chow, L Q M ^a,b   Bahlis, N ^a,b   Russell, J ^a,b   Chaudhry, A ^a,b   Morris, D ^a,b   Brown, C ^a,b   Stewart, Douglast A ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Autologous hematopoietic transplantation; Melphalan; Primary AL amyloidosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CISPLATIN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANADA; CLINICAL ARTICLE; COLON HEMORRHAGE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; HEART AMYLOIDOSIS; HEART FAILURE; HEMATOCHEZIA; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; MALE; MORTALITY; PATIENT ATTITUDE; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SAFETY; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AMYLOID; AMYLOIDOSIS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 30944467728     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705112     Document Type: Article

References (20)

1. Kyle RA, Bayrd ED. Amyloidosis: Review of 236 cases. Medicine (Baltimore) 1975; 54: 271-299.
2. Dubrey SW, Cha K, Anderson J et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141-157.
3. Kyle RA, Greipp PR, Garton JP et al. Primary systemic amyloidosis: comparison of melphalan/prednisone is colchicine. Am J Med 1985; 79: 708-716.
4. Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone and colchicine vs colchicine only. Am J Med 1996; 100: 290-298.
5. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 1997; 336: 1202-1207.
6. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light chain) amyloidosis: Survival and response in 25 patients. Blood 1998; 91: 3662-3670.
7. Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in system AL amyloidosis: A report on 21 patients. Br J Hematol 1998; 101: 766-769.
8. Gertz MA, Lacy MQ, Dispenzieri A. Treating AL amyloidosis (AL) with dose-intensive melphalan: Outcomes in 102 patients. Blood 1998; 82: 324a.
9. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: A status report. Bone Marrow Transplant 2000; 25: 465-470.
10. Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637-642.
11. Saba N, Sutton DM, Ross JH et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853-855.
12. Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood 2004; 103: 3960-3963.
13. Disperzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19; 2001: 3350-3356.
14. Mollee P, Wechalekar AD, Peireira D. Autologous stem cell transplantation in primary systemic amyloidosis: The impact of selection criteria on outcome. Bone Marrow Transplant 2004; 33: 271-277.
15. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-4282.
16. Skinner M, Sanchorawala V, Seldin DC et al. High dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: An 8 year study. Ann Intern Med 2004; 140: 85-93.
17. Gertz MA, Blood E, Vesole DH et al. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004; 34: 149-154.
18. Lachmann HJ, Booth DR, Booth SE et al. Misdiagnosis of hereditary amyloidosis as AL (primary) antyloidosis. N Engl J Med 2002; 346: 1786-1791.
19. Dispenzieri A, Gertz MA, Klye RA et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887.
20. Sanchorawala V, Wright DG, Seldin DC et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381-388.